$2.19
0.45% yesterday
Nasdaq, Sep 20, 10:01 pm CET
ISIN
US74584P1030
Symbol
PULM
Sector
Industry

Pulmatrix Inc Stock price

$2.19
+0.17 8.42% 1M
+0.54 32.91% 6M
+0.33 17.74% YTD
+0.02 0.92% 1Y
-13.07 85.65% 3Y
-15.37 87.53% 5Y
-2,362.81 99.91% 10Y
Nasdaq, Closing price Fri, Sep 20 2024
-0.01 0.45%
ISIN
US74584P1030
Symbol
PULM
Sector
Industry

Key metrics

Market capitalization $8.04m
Enterprise Value $-5.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.42
EV/Sales (TTM) EV/Sales -0.50
P/S ratio (TTM) P/S ratio 0.71
P/B ratio (TTM) P/B ratio 0.60
Revenue growth (TTM) Revenue growth 64.55%
Revenue (TTM) Revenue $11.39m
EBIT (operating result TTM) EBIT $-8.70m
Free Cash Flow (TTM) Free Cash Flow $-13.57m
Cash position $13.80m
EPS (TTM) EPS $-2.97
P/S forward 1.02
EV/Sales forward negative
Short interest 0.15%
Show more

Is Pulmatrix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Pulmatrix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Pulmatrix Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Pulmatrix Inc:

Buy
100%

Financial data from Pulmatrix Inc

Assets
Jun '24
16 16
Cash 14 14
Claims 0.64 0.64
Inventories - -
Other current assets Other current assets Current assets 1.20 1.20
0.14 0.14
Property, plant and equipment - -
Financial assets 0.05 0.05
Intangible Assets - -
Other fixed assets Other assets Fixed assets 0.09 0.09
Total Assets 16 16
Liabilities
Jun '24
Equity 13 13
2.47 2.47
Current liabilities 2.47 2.47
Non-current liabilities - -
Total Capital 16 16

In millions USD.

Don't miss a Thing! We will send you all news about Pulmatrix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pulmatrix Inc Stock News

Neutral
PRNewsWire
about one month ago
Completed series of transactions with MannKind Corporation validating iSPERSE ™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 FRA...
Neutral
PRNewsWire
4 months ago
Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.
Neutral
PRNewsWire
4 months ago
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE. Self-administered PUR3100 showed improved safety and tolerability relative to IV DHE.
More Pulmatrix Inc News

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Head office United States
CEO Peter Ludlum
Employees 22
Founded 2015
Website www.pulmatrix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today